X4 Pharmaceuticals announces promising early-stage trial results for its lead rare immune disorder drug candidate. The company's stock saw a significant surge in pre-market trading following the positive data release.
X4 Pharmaceuticals is a biotechnology company focused on treatments for rare immune system disorders.
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing